Home > Research > Publications & Outputs > Management of severe pain in terminal care.
View graph of relations

Management of severe pain in terminal care.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Management of severe pain in terminal care. / Bennett, Michael I.
In: Anaesthesia and Intensive Care Medicine, Vol. 6, No. 2, 01.02.2005, p. 65-68.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Bennett, MI 2005, 'Management of severe pain in terminal care.', Anaesthesia and Intensive Care Medicine, vol. 6, no. 2, pp. 65-68. https://doi.org/10.1383/anes.6.2.65.59088

APA

Vancouver

Bennett MI. Management of severe pain in terminal care. Anaesthesia and Intensive Care Medicine. 2005 Feb 1;6(2):65-68. doi: 10.1383/anes.6.2.65.59088

Author

Bennett, Michael I. / Management of severe pain in terminal care. In: Anaesthesia and Intensive Care Medicine. 2005 ; Vol. 6, No. 2. pp. 65-68.

Bibtex

@article{5bfca06467f04127be6ee709758b4f1f,
title = "Management of severe pain in terminal care.",
abstract = "Cancer pain occurs in about 30% of patients at diagnosis but increases in prevalence with advanced disease. Recent surveys suggest that over 80% of patients with advanced cancer have pain and about half of these patients experience pain that is inadequately controlled. This suggests that despite the 80% efficacy of standardized management approaches to cancer pain, patients with severe pain are likely to be encountered often in clinical practice. This is often the result of a combination of factors including inadequate pain assessment, under-dosing of medication, failure to educate and monitor patients and their carers, as well as a failure of medication to relieve pain. Assessment of a patient with cancer who is in pain should not differ from the assessment of any other patient with pain. Pain in a cancer patient may not be caused by cancer and opioids may be inappropriate. Treatment of cancer-related pain relies on a stepwise approach using non-opioid and opioid analgesics. Doses need to be titrated against analgesic effect and the presence of any adverse effects. Patients with cancer are often frail, elderly, and have some renal or hepatic impairment. They can be prone to the adverse effects of medicines. Neuropathic pain usually requires a combination of standard analgesic medicines and co-analgesic drugs and there is good evidence that this can result in good pain control. Patients with breakthrough (or episodic) pain are particularly challenging to treat and require additional approaches, such as radiotherapy, surgery or bisphosphonates.",
keywords = "pain, cancer, assessment, opioid, analgesics, neuropathic, breakthrough, management",
author = "Bennett, {Michael I.}",
year = "2005",
month = feb,
day = "1",
doi = "10.1383/anes.6.2.65.59088",
language = "English",
volume = "6",
pages = "65--68",
journal = "Anaesthesia and Intensive Care Medicine",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - Management of severe pain in terminal care.

AU - Bennett, Michael I.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Cancer pain occurs in about 30% of patients at diagnosis but increases in prevalence with advanced disease. Recent surveys suggest that over 80% of patients with advanced cancer have pain and about half of these patients experience pain that is inadequately controlled. This suggests that despite the 80% efficacy of standardized management approaches to cancer pain, patients with severe pain are likely to be encountered often in clinical practice. This is often the result of a combination of factors including inadequate pain assessment, under-dosing of medication, failure to educate and monitor patients and their carers, as well as a failure of medication to relieve pain. Assessment of a patient with cancer who is in pain should not differ from the assessment of any other patient with pain. Pain in a cancer patient may not be caused by cancer and opioids may be inappropriate. Treatment of cancer-related pain relies on a stepwise approach using non-opioid and opioid analgesics. Doses need to be titrated against analgesic effect and the presence of any adverse effects. Patients with cancer are often frail, elderly, and have some renal or hepatic impairment. They can be prone to the adverse effects of medicines. Neuropathic pain usually requires a combination of standard analgesic medicines and co-analgesic drugs and there is good evidence that this can result in good pain control. Patients with breakthrough (or episodic) pain are particularly challenging to treat and require additional approaches, such as radiotherapy, surgery or bisphosphonates.

AB - Cancer pain occurs in about 30% of patients at diagnosis but increases in prevalence with advanced disease. Recent surveys suggest that over 80% of patients with advanced cancer have pain and about half of these patients experience pain that is inadequately controlled. This suggests that despite the 80% efficacy of standardized management approaches to cancer pain, patients with severe pain are likely to be encountered often in clinical practice. This is often the result of a combination of factors including inadequate pain assessment, under-dosing of medication, failure to educate and monitor patients and their carers, as well as a failure of medication to relieve pain. Assessment of a patient with cancer who is in pain should not differ from the assessment of any other patient with pain. Pain in a cancer patient may not be caused by cancer and opioids may be inappropriate. Treatment of cancer-related pain relies on a stepwise approach using non-opioid and opioid analgesics. Doses need to be titrated against analgesic effect and the presence of any adverse effects. Patients with cancer are often frail, elderly, and have some renal or hepatic impairment. They can be prone to the adverse effects of medicines. Neuropathic pain usually requires a combination of standard analgesic medicines and co-analgesic drugs and there is good evidence that this can result in good pain control. Patients with breakthrough (or episodic) pain are particularly challenging to treat and require additional approaches, such as radiotherapy, surgery or bisphosphonates.

KW - pain

KW - cancer

KW - assessment

KW - opioid

KW - analgesics

KW - neuropathic

KW - breakthrough

KW - management

U2 - 10.1383/anes.6.2.65.59088

DO - 10.1383/anes.6.2.65.59088

M3 - Journal article

VL - 6

SP - 65

EP - 68

JO - Anaesthesia and Intensive Care Medicine

JF - Anaesthesia and Intensive Care Medicine

IS - 2

ER -